Bavarian Nordic A/S (BAVA.CO)
139.00DKK
11:20am EST
kr.-10.00 (-6.71%)
kr.149.00
kr.146.50
kr.146.50
kr.135.00
42,326
11,851
kr.291.50
kr.100.50
BAVA.CO
About
Overall
| Beta: | 1.31 |
| Market Cap (Mil.): | kr.1,187.97 |
| Shares Outstanding (Mil.): | 7.82 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| BAVA.CO | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 12.05 | 4.64 |
| EPS (TTM): | -1,560.64 | -- | -- |
| ROI: | -20.61 | 1.33 | 2.79 |
| ROE: | -22.20 | 2.17 | 3.51 |
Bavarian Nordic plans $50-60 mln rights issue
COPENHAGEN, Dec 1 (Reuters) - Danish biotech firm Bavarian Nordic A/S aims to raise up to 300 million crowns ($60.62 million) by issuing stock to existing shareholders to develop and market new drugs, it said on Tuesday.
Bavarian Nordic eyes Canada mkt for smallpox drug
COPENHAGEN, Nov 30 (Reuters) - Danish biotechnology firm Bavarian Nordic aims to seek approval next year to sell its smallpox vaccine Imvamune in Canada, which would be its first market, the company said on Monday.
STOCKS NEWS EUROPE-Biotech Bavarian Nordic down on capital need
Danish biotech company Bavarian Nordic falls 9.1 percent, distinctly underperforming peers in the MSCI European pharma, biotech and life sciences index , with analysts citing the company's tentative plans to seek to raise new capital.
UPDATE 1-Bavarian to file new claim vs Oxford Biomedica
COPENHAGEN, Jan 12 (Reuters) - Denmark's Bavarian Nordic said on Monday it would file a new patent infringement complaint in its suit against Britain's Oxford BioMedica after a United States judge dismissed the first allegation.
European biotech hurting but lucky few to win big
By Ben Hirschler, European Pharmaceuticals Correspondent - Analysis
European biotech hurting but lucky few to win big
By Ben Hirschler, European Pharmaceuticals Correspondent - Analysis
European biotech hurting but lucky few to win big
LONDON (Reuters) - It promises to be a lousy year for many of Europe's cash-strapped biotechnology companies, but a lucky few stand to hit the jackpot in deals with 'Big Pharma'.
STOCKS NEWS EUROPE-Commerzbank down; government to take stake
STOCKS NEWS Reuters Results diary
STOCKS NEWS EUROPE-Heijmans shares up 46 pct after land sale
STOCKS NEWS Reuters Results diary
STOCKS NEWS EUROPE-Management Consulting up after trading update
STOCKS NEWS Reuters Results diary
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
